tert-butyl 3-[(3-chloroisoquinolin-5-yl)amino]but-2-enoate | 1245932-28-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: tert-butyl 3-[(3-chloroisoquinolin-5-yl)amino]but-2-enoate
• CAS: 1245932-28-8
• 化学式: C₁₇H₁₉ClN₂O₂
• 分子量: 318.803
• InChiKey: SWOKAWGJDTWOSZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.55
• 重原子数：
  22.0
• 可旋转键数：
  3.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  51.22
• 氢给体数：
  1.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  tert-butyl 3-[(3-chloroisoquinolin-5-yl)amino]but-2-enoate 在 copper diacetate 、 palladium diacetate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.17h， 以68%的产率得到8-氯-2-甲基-1H-吡咯并[2,3-f]异喹啉-3-羧酸叔丁酯
  参考文献：
  名称：

  In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part I

  摘要：

  Pyrrolo[2,3-f]isoquinoline based amino acids, tetracyclic lactams and cyclic ketone analogues are described as novel MK2 inhibitors with IC(50) as low as 5 nM and good selectivity profiles against a number of related kinases including ERK, p38 alpha and JNKs. TNF alpha release was suppressed from human peripheral blood mononuclear cells (hPBMCs), and a representative compound inhibited LPS induced TNF alpha release in mice illustrating the potential of this series to provide orally active MK2 inhibitors. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.04.024
• 作为产物：
  描述：

  乙酰乙酸叔丁酯 、 3-氯-5-氨基异喹啉 在 溶剂黄146 作用下， 反应 4.0h， 以66%的产率得到tert-butyl 3-[(3-chloroisoquinolin-5-yl)amino]but-2-enoate
  参考文献：
  名称：

  In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part I

  摘要：

  Pyrrolo[2,3-f]isoquinoline based amino acids, tetracyclic lactams and cyclic ketone analogues are described as novel MK2 inhibitors with IC(50) as low as 5 nM and good selectivity profiles against a number of related kinases including ERK, p38 alpha and JNKs. TNF alpha release was suppressed from human peripheral blood mononuclear cells (hPBMCs), and a representative compound inhibited LPS induced TNF alpha release in mice illustrating the potential of this series to provide orally active MK2 inhibitors. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.04.024

文献信息

• ORGANIC COMPOUNDS
  申请人：Revesz Laszlo

  公开号：US20100069360A1

  公开（公告）日：2010-03-18

  A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: wherein the groups R1, R2, R3, R7 and X are as defined in the specification.

  化合物(I)的公式或其药学上可接受的盐或前药酯：其中，基团R1、R2、R3、R7和X如规范所定义。
• PYRROLO ISOQUINOLINES AS KINASE INHIBITORS
  申请人：NOVARTIS AG

  公开号：EP2064212A1

  公开（公告）日：2009-06-03
• [EN] PYRROLO ISOQUINOLINES AS KINASE INHIBITORS<br/>[FR] PYRROLO ISOQUINOLINES COMME INHIBITEURS DE KINASE
  申请人：NOVARTIS AG

  公开号：WO2008025512A1

  公开（公告）日：2008-03-06

  [EN] A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: wherein the groups R1, R2, R3, R7 and X are as defined in the specification.
  [FR] L'invention concerne un composé représenté par la formule (I) ou un sel acceptable du point de vue pharmaceutique ou un ester promédicament de celui-ci : où les groupes R1, R2, R3, R7 et X sont tels que définis dans la description.